PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection

[Guest guest]

PSI-938 Receives Fast Track Designation from the FDA for the Treatment of

Chronic Hepatitis C Infection

From the PharmaLive.com News Archive - Aug. 24, 2011

Pharmasset, Inc. has received fast track designation from the U.S. Food and

Drug Administration (FDA) for PSI-938 for the treatment of chronic hepatitis C

virus (HCV) infection. PSI-938 is an oral guanosine nucleotide analog

polymerase inhibitor of HCV.

[Guest guest]

PSI-938 Receives Fast Track Designation from the FDA for the Treatment of

Chronic Hepatitis C Infection

From the PharmaLive.com News Archive - Aug. 24, 2011

Pharmasset, Inc. has received fast track designation from the U.S. Food and

Drug Administration (FDA) for PSI-938 for the treatment of chronic hepatitis C

virus (HCV) infection. PSI-938 is an oral guanosine nucleotide analog

polymerase inhibitor of HCV.

[Guest guest]

PSI-938 Receives Fast Track Designation from the FDA for the Treatment of

Chronic Hepatitis C Infection

From the PharmaLive.com News Archive - Aug. 24, 2011

Pharmasset, Inc. has received fast track designation from the U.S. Food and

Drug Administration (FDA) for PSI-938 for the treatment of chronic hepatitis C

virus (HCV) infection. PSI-938 is an oral guanosine nucleotide analog

polymerase inhibitor of HCV.

[Guest guest]

PSI-938 Receives Fast Track Designation from the FDA for the Treatment of

Chronic Hepatitis C Infection

From the PharmaLive.com News Archive - Aug. 24, 2011

Pharmasset, Inc. has received fast track designation from the U.S. Food and

Drug Administration (FDA) for PSI-938 for the treatment of chronic hepatitis C

virus (HCV) infection. PSI-938 is an oral guanosine nucleotide analog

polymerase inhibitor of HCV.